LB Pharmaceuticals, a Phase 3 biotech developing therapies for neuropsychiatric diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
LB Pharmaceuticals' lead candidate LB-102, is a Phase 3-ready oral small molecule that it is developing to treat acute schizophrenia, a chromic disease characterized by hallucinations and delusions that affects roughly 1% of the US population. After achieving its primary endpoint of a change in the Positive and Negative Syndrome Scale at week four in its 359-patient Phase 2 trial, LB Pharmaceuticals expects to begin a Phase 3 trial in the 1Q26.
The New York, NY-based company was founded in 2015 and plans to list on the Nasdaq under the symbol LBRX. Leerink Partners, Piper Sandler, and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.